Zhongguancun: Subsidiary company's application for marketing approval of controlled-release quetiapine hydrochloride tablets has been accepted.

Zhongguancun announced that its subsidiary company, Beijing Huasu Pharmaceutical, recently received a "Notice of Acceptance" issued by the National Medical Products Administration for its application for the market approval of its sustained-release sertraline hydrochloride tablets. This drug is used for treating depression with or without symptoms of anxiety. As of the date of the announcement, the project has accumulated research and development expenses of 5.35 million RMB. If successfully approved, it will enhance the company's competitiveness in the market and have a positive impact on the company's operational performance.